Quantumup
Sep 30, 12:46 PM
Citizens reiterated
$IMMX Market Outperform-
$23 on what it believes could be best-in-class results in relapsed/refractory AL amyloidosis and continues to be buyers.
$REGN $ABBV JNJ SNY AZN
Citizens said in its note to investors: Yesterday, Immix reported interim results based on all 45 patients treated in the NEXICART-2 trial, showcasing what we believe could be best-in-class results in relapsed/refractory AL amyloidosis.
The company concurrently raised
$125MM in an underwritten offering from dedicated marquee healthcare investors.
Based on the conference call and the capital raised, we remain confident in the BLA submission for NXC-201 in 1H27.
With a potential commercial launch in 2028, the initiation of a front-line study slated for 2027, and a solid cash position of
$357.1MM (proforma), we believe Immix represents an attractive investment opportunity and continue to be buyers amidst the current weakness in shares.
